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The pathogenesis of alcoholic steatohepatitis (ASH) involves ethanol-induced aberrations in hepatic methionine metabolism that
decrease levels of S-adenosylmethionine (SAM), a compound which regulates the synthesis of the antioxidant glutathione and is
the principal methyl donor in the epigenetic regulation of genes relevant to liver injury. The present paper describes the effects
of ethanol on the hepatic methionine cycle, followed by evidence for the central role of reduced SAM in the pathogenesis of ASH
according to clinical data and experiments in ethanol-fed animals and in cell models. The efficacy of supplemental SAM in the
prevention of ASH in animal models and in the clinical treatment of ASH will be discussed.
1. Introduction
Alcoholic steatohepatitis (ASH) represents the intermedi-
ate stage of liver injury in the progression of steatosis,
inflammation, and hepatocellular apoptosis and necrosis that
occurs in the development of alcoholic cirrhosis. This paper
will address the role of ethanol-induced aberrant hepatic
methionine metabolism in the pathogenesis of ASH, in
particular through its epigenetic effects on the expressions
of genes relevant to alcoholic liver injury. Initially, we will
discuss the normal hepatic methionine metabolic cycle,
including its interactions with folate, vitamin B12, and
vitamin B6, and its relevance to the epigenetic regulation
of gene expression. This will be followed by experimental
evidence for multiple effects of ethanol on the methionine
metabolic cycle that lead to liver injury through altered
methylation and expressions of genes relevant to steatosis,
apoptosis, and oxidative stress. We will summarize data
from experimental and clinical studies that support these
concepts.
2. Normal Hepatic Methionine Metabolism
Hepatic methionine metabolism can be visualized in two
parts, the transmethylation cycle for production of S-
adenosylmethionine (SAM) and its metabolism to homo-
cysteine and the transsulfuration pathway for the reduc-
tion of homocysteine for the synthesis of glutathione
(GSH) (Figure 1). Endogenous 5-methyltetrahydrofolate (5-
MTHF) that is derived from dietary folate is substrate for
the initial vitamin-B12-dependent reaction of methionine
synthase (MS) that converts homocysteine to methionine.
The additional pathway of betaine homocysteine methyl-
transferase (BHMT) uses the choline product betaine as
substrate with homocysteine for methionine synthesis and
is considered a salvage pathway when MS is compromised
by toxins including ethanol. Methionine is metabolized to
SAM by methionine adenosyltransferase (MAT), which is a
product of the MAT1A gene in adult liver. SAM is utilized at
a rate of 6–8 grams per day [1], primarily by differentmethyl-
transferase reactions that include phosphatidylethanolamine
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Figure 1: Normal hepatic methionine metabolism. 5-MTHF:
5-methyltetrahydrofolate; THF: tetrahydrofolate; MS: methion-
ine synthase; BHMT: betaine hydroxy methyltransferase; DMG:
dimethylglycine; MAT: methionine adenosyl transferase; SAM: S-
adenosylmethionine; MT: methyltransferase; PE: phosphatidyleth-
anolamine; PEMT: phosphatidylethanolamine methyltransferase;
PC: phosphatidylcholine; SAH: S-adenosylhomocysteine; SAHH:
SAH hydrolase; CβS: cystathionine beta synthase; ABU: α-amino-
butyrate; GSH: glutathione.
transferase (PEMT) to yield phosphatidylcholine (PC) and
many others that methylate gene-specific DNA and various
histone residues. In addition, SAM levels are regulated by
the activity of glycine-n-methyltransferase (GNMT) with
sarcosine as its end product (not shown in Figure 1). While
SAM is the sole substrate for methyltransferase reactions,
its product S-adenosylhomocysteine (SAH) is the principal
inhibitor of the same reactions. Consequently, the SAM-to-
SAH ratio is used conveniently as an index of methylation
capacity since the Km and Ki for most of these reactions
are in similar range [2]. SAH is hydrolyzed to homocysteine
by SAH hydrolase (SAHH), which is a reversible enzyme
depending upon the abundance of each product. The initial
reaction in the transsulfuration pathway is facilitated by SAM
and involves the reduction of homocysteine through the
cystathionine beta synthase (CβS) reaction to cystathionine
[3]. Both CβS and the subsequent cystathionase reaction
require vitamin B6 as cofactor. Therefore, it may be predicted
that conditions that limit the production of SAM and the
availability of vitamin B6 reduce the production of GSH
and its antioxidant properties. Summarizing the key points,
homocysteine is regulated by three enzymes, MS, SAHH,
and CβS, each of which can be compromised to result in
homocysteine elevation which is involved in the pathogenesis
of ASH. The metabolite SAM plays a key role in regulating
gene methylation and expression and a second one by
regulating the production of the principal antioxidant GSH.
3. Effects of Ethanol Exposure on Hepatic
Methionine Metabolism
There is abundant and accumulating evidence that experi-
mental ethanol exposure and chronic alcoholism influence
the expressions and activities of several enzymes in the
hepatic methionine cycle. For example, transcript expres-
sions of MS, MAT1A, and CβS were decreased in liver
biopsies from ASH patients [4], while decreased expressions
and activities of MS, MAT1A, and SAHH, but increased
GNMT, were found in chronic ethanol-fed micropigs with
histologically proven ASH [5]. Reduced activities of MS with
compensatory increase in BHMT expressions and activities
were also found in ethanol-fed rats [6–8]. Since MAT1A
is susceptible to oxidation and nitrosylation of its cysteine
121 residue, its reduced activity in ASH may be attributed
to the generation of reactive oxygen species (ROS) that are
produced by the ethanol metabolizing enzyme cytochrome
p4502E1 (CYP2E1) [9, 10]. Thus, since SAM regulates the
generation of GSH through its facilitating effect on CβS
[3], the reduced antioxidant potential caused by reduced
GSH would predictably decrease the effectiveness of MAT1A
to generate SAM. These relationships were supported by
in vitro studies in chemically treated primary hepatocytes
in which elevation of prooxidant CYP2E1 was associated
with reduced SAM levels [11]. Also, studies in ethanol-fed
baboons and micropigs showed close correlations between
liver levels of GSH and SAM [12, 13].
4. Effects of Aberrant Methionine Metabolism
on the Pathogenesis of ASH
The conventional understanding of the pathogenesis of ASH
includes a series of events that are triggered by ethanol-
induced transport of enterotoxic lipopolysaccharide (LPS)
from the intestine to hepatic Kupffer cells that are in
turn induced to release cytokines such as tumor necrosis
factor alpha (TNFα) which initiates pathways of hepatocyte
apoptosis, inflammation, and necrosis. These processes are
facilitated by the effect of the ethanol metabolizing hepato-
cyte enzyme CYP2E1 which is a powerful producer of ROS
[14]. In addition, the metabolism of ethanol by alcohol to
acetaldehyde alters the NADH/NAD redox potential which
promotes steatosis through its effects on fatty acid oxidation
in the liver [15]. Steatosis, which is an early sign in devel-
opment of ASH, represents the combination of increased
hepatic lipogenesis and decreased fatty acid oxidation and
reduced triglyceride export. Many of these avenues of injury
have been linked to ethanol-induced aberrant methionine
metabolism in experimental animal models, as described
below.
Studies that used the model of the intragastric ethanol-
fed C57BL6 mouse linked enhanced lipogenesis and apop-
tosis to hyperhomocysteinemia, which is known to trigger
endoplasmic reticulum (ER) stress pathways that include
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upregulation of the chaperone glucose-regulated protein
(GRP78), the transcription factor sterol response element
binding protein (SREBP1-c) and its downstream lipogenesis
genes, and the growth arrest and DNA damage (GADD153)
pathway for apoptosis. Since the histopathology of steatosis
and apoptosis and these gene activations were prevented by
concomitant provision of betaine which lowered homocys-
teine through the BHMT salvage pathway (Figure 1), the
authors concluded that there is a specific role for ethanol-
induced hyperhomocysteinemia in the pathogenesis of ASH
by activation of ER stress pathways [16]. More recent studies
in the ethanol-fed rat model of ASH associated apoptosis
with increased liver SAH and steatosis with reduced activity
of PEMT which regulates triglyceride export from the liver
[17–19]. Others associated apoptosis in ethanol-fed mice
with increased levels of SAH which sensitized isolated
primary hepatocytes to the effects of TNFα [20], while a
later study in the same model associated this effect with
reduced mitochondrial SAM (mSAM) caused by competitive
inhibition of its mitochondrial transport by elevated SAH
[21]. The original finding of a mitochondrial transporter
for cytoplasmic SAM that is inhibited by SAH [22] was
complemented by discovery of a mitochondrial GSH trans-
porter that is inactivated by ethanol but is sustained by
coadministration of SAM [23]. A role for mSAM in preven-
tion of the prooxidant effects of ethanol was supported by
intervention studies that demonstrated a protective effect of
SAM against decreased mitochondrial respiration [24] and
increased levels of mitochondrial superoxide and inducible
nitric oxide synthase (iNOS) [25]. SAM may also play a role
in prevention of hepatocellular carcinoma (HCC) in ALD by
inhibition of angiogenesis genes [26].
5. Role of Altered Gene Methylation Capacity in
the Pathogenesis of ASH
The pathogenesis of ASH includes activations of many genes
involved in liver injury, each of which are potentially and
epigenetically regulated by alterations in hepatic levels of
SAM and SAH and their methylation capacity ratio. Our
laboratory explored these relationships in two ethanol-fed
animal models, the micropig and the genetically altered
mouse. An initial study demonstrated the suitability of the
micropig for study of the pathogenesis of ASH, in which its
characteristic histopathology was induced by feeding ethanol
at 40% of kcal over 12 months [27] together with progressive
increase in serum homocysteine levels and reduced gene
methylation capacity as shown by decrease in the liver SAM
and the SAM-to-SAH ratio [28]. Subsequently, we included
folate deficiency in the dietary regimen in order to accentuate
changes in methionine metabolism through reduction of the
initial methyl donor 5-MTHF (Figure 1), with the additional
rationale of the well-known association of folate deficiency
with chronic alcoholism [29, 30]. In contrast to the findings
in the previous study [27] only 3 months were required
for the development of the histopathology of ASH, while
increases in timed serum homocysteine levels and lowering
of the hepatic SAM-to-SAH ratio were the greatest in the
group fed the combined folate-deficient and ethanol diet
compared to groups fed either diet alone [12]. Using liver
samples from the same groups of micropigs, we found
progressive increase in transcript and protein levels of
genes relevant to steatosis and liver injury from micropigs
fed control, folate-deficient, ethanol, and ethanol with
folate-deficient diets, together with increased expressions
of CYP2E1 and ER stress pathway genes for the marker
GRP 78, lipogenesis that included SREBP 1-c and fatty
acid synthase (FAS), and apoptosis including GADD 153
[31]. The finding that these gene expressions correlated with
changes in the SAM-to-SAH ratio supported the relationship
of the pathogenesis of ASH to ethanol-induced reduction of
gene methylation capacity. This concept was supported by
subsequent studies in which the coadministration of SAM
sustained normal histology while preventing changes in the
SAM-to-SAH ratio, and activations of the same ER stress
genes for lipogenesis and apoptosis [32], as well as genes
relevant to oxidative liver injury including CYP2E1, nicoti-
namide adenine dinucleotide phosphate oxidase (NOX1),
and inducible nitric oxide synthase (iNOS) [33].
6. ASH Is Mediated through the
Epigenetic Effects of Ethanol-Induced
Altered Methionine Metabolism
Epigenetics refers to the effects of external factors on the
expressions of genes that are unrelated to changes in their
DNA sequences. Gene expression is regulated at the levels
of both DNA and its histone infrastructures that exist
within nuclear chromatin. In the context of the present
paper, such changes can be attributed to the regulatory
effects of increased or decreased methylation on DNA and
histones, since folate contains the parent methyl group and
SAM is the principal methyl donor in all methyltransferase
reactions (Figure 1). As described in recent reviews, the
effect of chronic ethanol exposure on the activation or
suppression of selected ASH-related genes can be ascribed to
different methylation effects at histone 3 lysine (K) residues,
whereby gene expression is enhanced by methylation at
H3meK4 but is silenced by methylation at H3meK9 [34, 35].
Furthermore, ethanol exposure enhances gene expression
by acetylation at H3AcK9[35], whereas sirtuin1, a known
histone de-acetylase, is reduced in livers of ethanol-fed mice
[36]. Therefore, the effects of ethanol exposure on specific
histone methyltransferases, acetylases, and deacetylases may
be crucial to the epigenetic control of the expressions of genes
relevant to liver injury. Further epigenetic regulation occurs
at the level of DNA, where increased methylation of pro-
moter region cytosine residues suppresses gene expression
and vice versa. For example, global DNA hypomethylation
occurred in the ethanol-fed SAM-deficient rat [37] and
MAT1A knockout mouse with enhanced carcinogenesis [38],
as well as in our folate-deficient chronic alcoholic micropig
model in association with increased DNA oxidation and
strand breaks [12]. Others found reduced expression of the
DNA methyltransferase DNMT3b that correlated negatively
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with increased blood alcohol levels in chronic alcoholics
together with increased global DNA methylation [39].
We explored epigenetic regulation of ASH in a novel
model of the C57BL6 CβS-deficient mouse fed intragastric
ethanol at 37% of kCal for 4 weeks. This model is particularly
relevant since, as noted above, the same method was used
to induce ASH in C57BL6 wild-type mice with findings of
altered methionine metabolism, all of which were corrected
by the methyl donor betaine [16]. Since CβS heterozygosity
is known to increase serum homocysteine levels [40] and
ethanol exposure inhibits MS expression and activity [5,
6] we reasoned that both ethanol exposure and genotype
would accentuate aberrant methionine metabolism with the
greatest effect in the combined group. Our study showed all
the histopathological features of severe ASH in the combined
ethanol-fed heterozygous group, which also showed the
greatest reduction in the SAM-to-SAH ratio and the greatest
increase in expressions of the ER stress genes SREBP 1-
c, GRP78, and GADD153 [41]. While immunohistological
staining of liver slices showed that methylated histone residue
H3K9 was specifically reduced in centrilobular regions which
were the sites of maximal steatosis in the ethanol-fed
heterozygous group, the chromatin immunoprecipitation
(ChIP) assay using antibody to H3K9 showed its reduced
presence in the promoter regions of the same ER stress
genes. Since H3K9 associates with gene suppression, its
reduced presence in liver from the combined ethanol-fed
heterozygous group is consistent with activation of these
genes. Furthermore, the transcript expression of G9a, a
histone methyltransferase that is required for methylation
of K9 residues, was specifically reduced in both ethanol-
fed groups in contrast to other K9 methyltransferases [41].
The mechanism for reduced expression of the histone
methyltransferase G9a is unclear, but others have shown
effects of ethanol-induced ROS on chromatin remodeling
as a mechanism for changes in histone acetylation reactions
[42]. Summarizing, these studies provided an epigenetic
mechanism for the relationship of ethanol-induced aberrant
methionine metabolism on the epigenetic regulation of
expression of selected ER stress genes that are relevant to
lipogenesis and apoptosis in ASH [41].
Using the ChIP assay in a mouse macrophage RAW
cell line and in vivo in LPS-treated mice, others showed
that SAM inhibited the LPS-induced activations of TNFα
and iNOS by blocking the binding of H3meK4 to the
promoter regions of these genes [43]. Data from two groups
suggest epigenetic regulation of proteosome inhibition as a
mechanism for enhanced liver injury. In one study in an
ethanol-fed rat model, proteosome inhibition was associated
with alterations in histone acetylation and methylation [44],
whereas methylation of a specific subunit by provision of
SAM prevented proteosome degradation in ethanol-exposed
hepatocytes [45].
7. Clinical Studies
A study of patients with cirrhosis of diverse etiologies
including alcoholism found significant elevations in serum
homocysteine and cystathionine, which was suggestive of
a block in the transsulfuration pathway for homocysteine
elimination and production of GSH [46]. Compared to
healthy subjects, we found increased serum homocysteine
levels in alcoholics with or without ASH in association
with elevated serum SAH levels [47]. While others have
described elevated homocysteine levels in chronic alcoholics
in association with deficiencies of folate and vitamin B6
[48], we found that ASH patients also had marked increase
in serum levels of cystathionine, the substrate for vitamin-
B6-dependent cystathionase (Figure 1), with comparable
reduction in its product α-aminobutyrate (ABU). Further-
more, cystathionine levels and the ABU-to-cystathionine
ratio correlated with vitamin B6 levels and the ABU-to-
cystathionine ratio was a positive predictor of the presence
of ASH among alcohol drinkers [47].
The growing experimental evidence linking impaired
methionine metabolism with the onset and development of
alcoholic liver disease prompted several clinical trials that
attempted to demonstrate a role for SAM in its treatment.
One study showed that 15 days of intravenous SAM at
2 g/day increased red blood cell GSH in 20 patients with ASH
[49]. Hepatic GSH levels were low in liver biopsies from 17
patients with ASH or other chronic liver diseases and were
normalized by SAM treatment at 1.2 g/day in a 6-month
controlled study [50]. A later 2-year multicenter European
trial of 123 ASH patients found reduction in mortality
or incidence of liver transplant from 30% in the placebo
group to 16% in the SAM group, which was significant
after exclusion of Childs class C patients from the analysis
[51]. A 2006 meta-analysis of 9 studies found insufficient
evidence for the effective use of SAM in the treatment
of alcoholic liver disease [52]. Whereas the PC derivative
polyenylphosphatidylcholine (PPC) was known to restore
liver SAM levels in ethanol fed rats [53], there was no benefit
of this compound according to liver histopathology in 412
ASH patients who underwent liver biopsies at baseline and
after 24 months of treatment [54].
We conducted a randomized treatment trial in 26 ASH
patients who participated in our baseline study [47] and
then received SAM at 1.2 g/d or placebo daily for 24 weeks
[55]. All biochemical parameters of liver function improved
over time with no differences between the groups. Although
serum SAM levels rose over time with treatment, there were
no changes in other methionine metabolites in either group.
Furthermore, there were no differences between groups in
histopathology scores for steatosis, inflammation, or fibrosis
in 14 patients who underwent liver biopsies before and after
treatment [55].
Summarizing, the results from several clinical trials of
SAM in treatment of ASH are inconclusive as to its effect.
Previous positive studies included patients with other causes
of liver disease and showed no comprehensive histological
data on the efficacy of SAM. While our study is the
first to provide data on potential changes in methionine
metabolite levels and documents the lack of differences
in histopathology, its limitations include relatively short
exposure to SAM and relatively small number of subjects.
Unlike studies in animal models that showed the efficacy of
SAM in prevention of ASH [13, 32, 33], the use of SAM in the
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treatment of established liver disease may be compromised
by lack of retention of SAM by injured hepatocytes as well
as decreased numbers of normally functioning hepatocytes.
Also, based on our methionine metabolite findings at base-
line [47] and the role of vitamin B6 in the transsulfuration
pathway (Figure 1), there may be a requirement for vitamin
B6 supplementation in addition to SAM in longer-term
treatment of ASH.
8. Conclusions
Abundant evidence now exists for the central role of aberrant
hepatic methionine metabolism in the pathogenesis of ASH.
Ethanol and its ROS products inhibit key enzymes in
the methionine cycle, in particular those involved in the
synthesis of SAM. Since SAM is the principal methyl donor
for histones and DNA and facilitates the production of
GSH, its reduction influences the methylation and hence
epigenetic regulation of many genes involved in alcoholic
liver injury as well as the capacity for antioxidant defense
in the pathogenesis of ASH. Whereas SAM supplementation
has been proven to prevent ASH and its mechanisms in
experimental animal models, clinical trials have failed to
demonstrate a definitive effect of SAM in the treatment of
established ASH.
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